<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335898">
  <stage>Registered</stage>
  <submitdate>26/08/2010</submitdate>
  <approvaldate>7/09/2010</approvaldate>
  <actrnumber>ACTRN12610000743066</actrnumber>
  <trial_identification>
    <studytitle>Reduction of Surgical Site Infection in Cardiac Surgery using a Microbial Sealant-A  Controlled Study</studytitle>
    <scientifictitle>In coronary artery bypass patients requiring greater than 2 lengths of saphenous vein for conduit does the application of a cyanoacrylate surgical sealant prior to leg wound incision decrease wound infection rates scored at 1 month
when compared to the contralateral leg wound in the same patient.</scientifictitle>
    <utrn>U1111-1116-7201</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Surgical Site Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Application of a cyanoacrylate microbial surgical sealant to the skin surface immediately prior to skin incision for removal of the long saphenous vein for coronary artery bypass surgery. 
Applied directly from sterile container with sponge applicator. Probable mechanism of action is the fixation of microorganisms within hair follicles and sweat glands, thus reducing quantitatively the contamination of the incision.</interventions>
    <comparator>The contralateral leg wound in the same patient. This is managed in an identical fashion to the treatment (ie Sealant applied leg) other than the application of the sealant.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Wound infection, scored by blinded observors according to Southampton wound score system</outcome>
      <timepoint>At 1 month following surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>wound swab microbial culture</outcome>
      <timepoint>At 5 days post operatively.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Isolated Coronary Artery bypass patients requiring greater than 2 lengths of saphenous vein conduit.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Peripheral vascular disease, long saphenous vein abnormality, leg skin lesions or ulcers, prior sensitivity to cyanoacrlate, acetone or formaldehyde containg products, non consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>All patients presenting for isolated coronary artery bypass grafts (CABG) requiring &gt; 2 lengths of saphenous conduit, without exclusion features. allocation not concealed. Alternate application of sealant sequentially to left or right leg in consecutive patients.</concealment>
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>14/07/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ian Gilfillan</primarysponsorname>
    <primarysponsoraddress>Fremantle Hospital
Alma Street
Fremantle
Western Australia 6160</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Ian Gilfillan</fundingname>
      <fundingaddress>Fremantle Hospital
Alma Street
Fremantle
Western Australia 6160</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A trial to see if the use of a cyanoacrylate ("Superglue") sealant applied to the skin prior to the surgical incsion can reduce the incidence of post operative wound infections.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Department Of Health, South Metropolitan Area Health, Human Research Ethics Committee</ethicname>
      <ethicaddress>Fremantle hospital
Alma Street
Fremantle
WA 6160</ethicaddress>
      <ethicapprovaldate>2/07/2008</ethicapprovaldate>
      <hrec>08/90</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ian Gilfillan</name>
      <address>Fremantle hospital
Alma Street
Fremantle
Western Australia
6160</address>
      <phone>+61894313337</phone>
      <fax />
      <email>ian.gilfillan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ian Gilfillan</name>
      <address>Fremantle hospital
Alma Street
Fremantle
Western Australia
6160</address>
      <phone>+61894313337</phone>
      <fax />
      <email>ian.gilfillan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ian Gilfillan</name>
      <address>Fremantle hospital
Alma Street
Fremantle
Western Australia
6160</address>
      <phone>+61894313337</phone>
      <fax />
      <email>ian.gilfillan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>